Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways

Table 1 Characteristics of OS case series.

Case	Gender	Histology	Grade	Site	BRAF mutations	P-ERK1/2 *	MCL-1 *	P-ERM *
1	M	OSTEOBLASTIC	G4	TIBIA	-	-	+	+
2	M	OSTEOBLASTIC	G4	FEMUR	-	-	+	-
3	F	OSTEOBLASTIC	G4	FEMUR	-	-	-	-
4	M	OSTEOBLASTIC	G4	TIBIA	-	-	-	+
5	M	OSTEOBLASTIC	G4	HOMER	596 delA	-	-	-
6	F	OSTEOBLASTIC	G4	TIBIA	-	-	+	-
7	F	OSTEOBLASTIC	G4	FEMUR	-	-	+	+
8	M	OSTEOBLASTIC	G4	FEMUR	-	-	++	+
9	M	OSTEOBLASTIC	G4	TIBIA	-	-	+	+
10	M	OSTEOBLASTIC	G4	FEMUR	-	-	+	+
11	M	OSTEOBLASTIC	G4	FEMUR	-	++	++	+
12	F	OSTEOBLASTIC	G4	FEMUR	-	+	-	-
13	M	OSTEOBLASTIC	G4	FEMUR	H608L	++	++	+
14	M	OSTEOBLASTIC	G4	FEMUR	-	+	+	-
15	M	OSTEOBLASTIC	G4	HOMER	-	++	++	+
16	M	OSTEOBLASTIC	G4	TIBIA	-	++	+	+
17	F	OSTEOBLASTIC	G4	FEMUR	-	+	+	+
18	M	OSTEOBLASTIC	G4	FEMUR	-	+	++	-
19	F	OSTEOBLASTIC	G4	HOMER	-	++	+	++
20	M	OSTEOBLASTIC	G4	TIBIA	-	+	+	+
21	M	OSTEOBLASTIC	G4	FEMUR	-	++	++	+
22	M	OSTEOBLASTIC	G4	FEMUR	G615R	++	++	++
23	M	FIBROBLASTIC	G4	TIBIA	-	+	++	-
24	M	FIBROBLASTIC	G4	FEMUR	-	++	-	+
25	M	OSTEOBLASTIC	G4	FEMUR	-	+	+	-
26	F	OSTEOBLASTIC	G3	HOMER	-	+	-	+
27	M	OSTEOBLASTIC	G4	FEMUR	-	+	+	++
28	M	OSTEOBLASTIC	G4	FEMUR	S602Y	+	+	+
29	F	OSTEOBLASTIC	G4	HOMER	-	+	++	+
30	M	OSTEOBLASTIC	G4	TIBIA	-	++	++	++

Gender, histological subtypes, grading, site of tumor origin, immunohistochemical results of P-ERK1/2, MCL- 1 and P-ERM expression and BRAF exon 15 mutations of each osteosarcoma samples from patients. intensity of expression: (-)< 10% positive cells scored -, 10-50% positive cells scored +;> 50% positive cells and high staining intensity scored ++).

ISSN: 1476-4598